ReviewBreast cancer research and treatment1995
Chromosome 11q13 markers and D-type cyclins in breast cancer.
Review in Breast cancer research and treatment, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 69 citations in OpenAlex.
- Cinobufagin Exerts Anticancer Activity in Oral Squamous Cell Carcinoma Cells through Downregulation of ANO1.International journal of molecular sciences · 2021Article
- Inhibition of ANO1/TMEM16A induces apoptosis in human prostate carcinoma cells by activating TNF-α signaling.Cell death & disease · 2018Article
- Tumor Wide Horizontal Invasion Predicts Local Recurrence for Scrotal Extramammary Paget's Disease.Scientific reports · 2017Article
- Article
- Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers.American journal of translational research · 2016Article
- Effect of Crocin on Cell Cycle Regulators in N-Nitroso-N-Methylurea-Induced Breast Cancer in Rats.DNA and cell biology · 2015Article
- Prognostic significance of TMEM16A, PPFIA1, and FADD expression in invasive ductal carcinoma of the breast.World journal of surgical oncology · 2014Article
- Overexpression of cortactin increases invasion potential in oral squamous cell carcinoma.Pathology oncology research : POR · 2010Article
- FISH is more sensitive than Southern analysis at identifying increased levels of cyclin D1 gene amplified in breast cancer cell lines.Molecular biology reports · 2010Article
- Dominant expression of 85-kDa form of cortactin in colorectal cancer.Journal of cancer research and clinical oncology · 2006Article
- Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1.Proceedings of the National Academy of Sciences of the United States of America · 2001Article
- P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor.Proceedings of the National Academy of Sciences of the United States of America · 1999Article
- The "Spot 14" gene resides on the telomeric end of the 11q13 amplicon and is expressed in lipogenic breast cancers: implications for control of tumor metabolism.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.Molecular and cellular biology · 1997Article
- Cyclins and breast cancer.Journal of mammary gland biology and neoplasia · 1996Review
- Genetic analysis of breast cancer progression.Journal of mammary gland biology and neoplasia · 1996Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One in six primary human breast cancers has DNA amplification centered on the cyclin D1 gene (CCND1) on chromosome 11q13. This genetic abnormality is preferentially associated with estrogen-receptor positive tumors and may define a sub-class of patients with an adverse prognosis. Although CCND1 has the credentials of a cellular oncogene, being a target for chromosomal translocation and retroviral integration, the 11q13 amplicon encompasses several other markers and CCND1 is not the only candidate for the key gene on the amplified DNA. To assess their relative importance, we have constructed a physical map of the amplified DNA and compared the extent and frequency of amplification across the region. Since it is likely that the gene providing the selective force for amplification will be expressed at elevated levels, we have also examined expression of both RNA and protein. By these criteria, cyclin D1 remains the strongest candidate for the key oncogene on the amplicon and we are currently investigating the functional consequences of its over-expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.